← Back to Clinical Trials
Recruiting NCT06656832

NCT06656832 Peripheral Drivers of Heart Failure Progression - The Prospective PEDAL-HF Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06656832
Status Recruiting
Phase
Sponsor University of Leipzig
Condition Heart Failure - NYHA II - IV
Study Type INTERVENTIONAL
Enrollment 1,000 participants
Start Date 2024-11-28
Primary Completion 2028-10-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Heart Failure network care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 1,000 participants in total. It began in 2024-11-28 with a primary completion date of 2028-10-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

PEDAL-HF is a registry-based randomized prospective multicenter study. The investigators plan to include 1000 patients who were recently admitted with acute decompensated heart failure at five tertiary heart clinics in Germany. For the randomised part, 750 patients will be randomized to care within a heart failure network or usual care. The primary endpoint of the randomized trial is change in NT-proBNP from baseline to 6 months of follow-up. All patients (randomized or not) will be followed for two years.

Eligibility Criteria

Inclusion Criteria: * Patients admitted to the participating study centres with acute decompensated heart failure (ADHF), defined as clinical signs and/or symptoms of heart failure * objective structural cardiac abnormalitites according to the ESC criteria. Exclusion Criteria: * Age \<18 years * pregnancy * any condition interfering with the informed consent process * patients placed in an institution by official or court order

Contact & Investigator

Central Contact

Rolf Wachter, MD

✉ rolf.wachter@medizin.uni-leipzig.de

📞 +49-341-97-12650

Frequently Asked Questions

Who can join the NCT06656832 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure - NYHA II - IV. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06656832 currently recruiting?

Yes, NCT06656832 is actively recruiting participants. Contact the research team at rolf.wachter@medizin.uni-leipzig.de for enrollment information.

Where is the NCT06656832 trial being conducted?

This trial is being conducted at Leipzig, Germany.

Who is sponsoring the NCT06656832 clinical trial?

NCT06656832 is sponsored by University of Leipzig. The trial plans to enroll 1,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology